ALK and non-small cell lung carcinoma: However, TKIs in NSCLC cases with ALK [9, 10], ROS1 [11], and RET fusion [12] and in pan-cancer with neurotrophic tyrosine receptor kinase genes 1/2/3 fusion [13] exhibited a tail plateau on the progression-free survival curve.